The expression of immune checkpoint ligands, such as PD-L1, PD-L2, B7-H3, and B7-H4, was notable for being heterogeneous across glioma grades and even within GBM (grade 4), indicating that monotherapy with these agents is likely to only benefit a subset of patients. This evidence concerns the gene PDCD1LG2 and central nervous system cancer.